Who
Patricia A. Martin
Director
Company insider
Files Form 4 as: Director, AN2 Therapeutics; Director, Cypherpunk Technologies.
In numbers
- Trades disclosed
- 47
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $386K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 12 May 2022
- Last trade
- 12 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Sep – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 13 Oct 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —389 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | CYPH Cypherpunk TechnologiesBiotechnology | SEC FORM 4 Sold | $193K50,000 at $3.86 | filing |
| 23 Sep 2026filed 25 Sep 2026 | CYPH Cypherpunk TechnologiesBiotechnology | SEC FORM 4 Sold | $193K50,000 at $3.86 | filing |
| 10 Jul 2026filed 10 Jul 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —766 at $0.00 | filing |
| 10 Jul 2026filed 10 Jul 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —766 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CYPH Cypherpunk Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CYPH Cypherpunk Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 10 Apr 2026filed 10 Apr 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,192 at $0.00 | filing |
| 10 Apr 2026filed 10 Apr 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,192 at $0.00 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,999 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —24,999 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,999 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —24,999 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,742 | filing |
News
No headline names them, or the companies they trade most, lately.